Clinical Trial Update: Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis

View source ↗

Summary

A clinical trial is evaluating the change in disease activity with risankizumab in adults with moderate to severe ulcerative colitis; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis | Status: RECRUITING